Based on clinical prognostic relevance, CYP4B1 showed significant activity in adrenocortical cancer as a tumor-suppressor with drug-sensitizing effects; in lung adenocarcinoma, it was associated with improved survival, whereas in lung squamous cell carcinoma, it correlated with poor prognosis and an immunosuppressive profile; in ovarian cancer, it was linked to recurrence and chemoresistance. This evidence concerns the gene CYP4B1 and adrenal cortex carcinoma.